Biogen Slovakia
Develops and commercializes medicines for serious diseases, serving patients and healthcare providers in Slovakia
Highlights
- ProfitableFY2025 net profit €106k · RÚZ
About Biogen Slovakia
Biogen Slovakia is the Slovak subsidiary of biotechnology company Biogen. It focuses on medicines and potential therapies for neurological, neuropsychiatric, specialized immunology and rare diseases.
The company serves patients and healthcare providers in Slovakia through its local pharmaceutical business. The supplied website does not specify its revenue model or particular products marketed in Slovakia.
The legal entity was founded in 2006 and is headquartered in Bratislava. Registry data identifies it as a subsidiary of a foreign group with 10–19 employees; the website includes a careers section but no specific vacancies.
Product: Medicines and potential therapies for serious diseases, including neurological, neuropsychiatric, immunological and rare diseases.
Financials
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | €3.1M | €3.3M | €3.4M | €3.3M | €3.0M |
| Growth | −4% | −3% | +2% | +10% | — |
| EBITDA | €263k | €317k | €295k | €289k | €264k |
| Operating profit | €213k | €271k | €260k | €246k | €205k |
| Net profit | €106k | €198k | €292k | €134k | €146k |
| Net margin | 3.4% | 6% | 8.6% | 4.1% | 4.9% |
| Personnel costs | €1.9M | €2.1M | €2.3M | €2.0M | €1.8M |
| Total assets | €3.0M | €3.0M | €2.8M | €2.5M | €2.4M |
| Cash | €2.4M | €2.2M | €889k | €1.5M | €1.7M |
| Liabilities | €511k | €651k | €627k | €606k | €504k |
| Equity | €2.5M | €2.4M | €2.2M | €1.9M | €1.9M |
As filed with RÚZ (Slovak register of financial statements). Each year links to its statement.
Public contracts
Contracts Biogen Slovakia signed since 1 Nov 2024, from the Slovak and Czech public contract registers. Values as published; amendments are not counted.
Customers
1 contract with 1 buyer · €2k
| Contracts | Value | |
|---|---|---|
| Trenčianska univerzita Alexandra Dubčeka v Trenčíne | 1 | €2k |
Open public tenders for Biogen Slovakia →
Latest contracts
- 12 Dec 2024 for Trenčianska univerzita Alexandra Dubčeka v Trenčíne · Sponzorská zmluva · €2k register
Jobs at Biogen Slovakia
Leadership
- Francesco Verolino · Konateľ (Managing director)Source: business register
- Martina Míková · Konateľ (Managing director)Source: business register
- Sérgio Ferreira Da Silva Teixeira · Konateľ (Managing director)Source: business register
More biotech & pharma companies
BIOHEM
Wholesale distribution of medicines, medical materials and diagnostic reagents to clinics and labs in SlovakiaYoung companyProfitableBiotika
Slovak manufacturer of penicillin and polymyxin B active pharmaceutical ingredients for pharma clientsSalary transparentBIOVETA SK
Veterinary medicines and animal-health products for veterinary professionals and distribution partnersProfitableNew on EvolcCatopharm
Imports German and Spanish veterinary preparations and supplementary feeds for cats, dogs and rabbits, sold through vetsProfitableNew on EvolcChiesi Slovakia
Pharmaceutical company marketing respiratory, neonatal and rare-disease medicines in SlovakiaProfitableEuropa Pharmaceutical
Generic medicines and vaccine solutions for healthcare providers and distributorsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content management
- Adobe Experience ManagerHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Privacy & consent
- CookiebotHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.